Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today!
NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
News Medical4d
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a four-day losing streak.